Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Plexiform Neurofibroma: early-phase trial registry

3 of 8 indexed Plexiform Neurofibroma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

8 US clinical trials · 3 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Plexiform Neurofibroma: 8 US clinical trials tracked, 3 recruiting.

Plexiform Neurofibroma is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Shanghai Fosun Pharmaceutical Industrial Development Co., running 1 of these trials.

Enrollment posture brief

Registry condition plexiform-neurofibroma

OPEN 3 | RECR 38% | LATE 0 | EARLY 4 | RANK #2176 | SPON 1

Nearest open-share peer: Acute-graft-versus-host Disease (38% recruiting · 8 trials)

Activity, Motor75%Achalasia50%Plexiform Neurofibroma (this)38%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%
Open-enrollment share among volume-matched conditions near Plexiform Neurofibroma

Plexiform Neurofibroma lists 3 open slots (38% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Plexiform Neurofibroma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Plexiform Neurofibroma is recruiting below its size-band peers.

    3 of 8 indexed trials (37.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Plexiform Neurofibroma trials is spread across many organizations.

    Shanghai Fosun Pharmaceutical Industrial Development Co. accounts for 1 of 8 trials (12.5%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Typical Plexiform Neurofibroma enrolment sits around 160 participants.

    Median target enrolment is 160 among the 8 trials that report a genuine target (sentinel values excluded). 3 of those (37.5%) plan for fewer than 100 participants.

  4. Plexiform Neurofibroma splits between interventional and observational designs.

    5 interventional and 3 observational studies make up this index (62.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 22

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 2

Named interventions

Most-linked intervention names on Plexiform Neurofibroma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Whole Body MRI Diagnostic test
1 trials
Mirdametinib (PD-0325901) oral capsule or dispersible tablet Drug
1 trials
FCN-159 Drug
1 trials
Liquid biopsy for MPNST development Diagnostic test
1 trials
Selumetinib Drug
1 trials
Avutometinib Drug
1 trials

US sites by state

Facility locations filed on Plexiform Neurofibroma trials. A trial with sites in several states counts in each.

California 3 trials
Maryland 2 trials
Massachusetts 2 trials
Illinois 2 trials
Georgia 2 trials
Florida 2 trials
Alabama 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Plexiform Neurofibroma page

8 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Plexiform Neurofibroma condition card totals 8 registered trials; most-linked intervention Whole Body MRI; top US site state District of Columbia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.